ENTITY
Mabpharm

Mabpharm (2181 HK)

23
Analysis
Industrials • Hong Kong
Mabpharm is a biopharmaceutical company specializing in the research, development, and manufacturing of monoclonal antibody drugs and biosimilars for cancer and autoimmune diseases. Its core products include CMAB009 Enlito, CMAB007 AomaiShu, and CMAB008 Leiting, which treat various conditions such as colorectal cancer, asthma, and rheumatoid arthritis. The company was founded in 2009 and is headquartered in Taizhou, Jiangsu, PRC.
more
bearish•Mabpharm
•17 May 2019 15:58

MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors

MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...

Logo
760 Views
Share
bearish•Mabpharm
•15 Apr 2019 11:34

MabPharm (迈博医药) IPO: Thoughts on Valuation (Part 2)

MabPharm is expected to launch its IPOsoon. In our previous insights (links provided below), we provided a detailed analysis of the company's core...

Logo
1k Views
Share
bearish•Mabpharm
•21 Feb 2019 13:45

MabPharma (迈博医药) IPO: Assembled for a Trade?

MabPharma, backed by Chinese private equity investor CDH, is seeking to list in Hong Kong. In this insight, we will discuss the following...

Logo
1.1k Views
Share
x